替诺福韦与恩替卡韦治疗慢性乙型肝炎的效果比较

Comparison of Tenofovir and Entecavir in the Treatment of Chronic Hepatitis B

目的:探究慢性乙型肝炎患者采用替诺福韦与恩替卡韦治疗的临床效果。方法:择取天水市张家川回族自治县第一人民医院2021年1—10月收治的100例慢性乙型肝炎患者作为研究对象,依据随机数字表法将其分为对照组(予以恩替卡韦治疗)与观察组(予以富马酸替诺福韦二吡呋酯片治疗),各50例。分析两组乙型肝炎病毒(HBV)-DNA(HBV-DNA)水平、肝功能、乙型肝炎e抗原(HBeAg)转阴率、总有效率。结果:治疗前,两组HBV-DNA水平对比,差异无统计学意义(P>0.05);治疗12、24、32周后,观察组HBV-DNA水平均低于对照组,差异均有统计学意义(P<0.05);治疗前及治疗32周后,两组肝功能指标比较,差异均无统计学意义(P>0.05);治疗12、24周后,观察组肝功能指标均优于对照组,差异均有统计学意义(P<0.05)。治疗32周后,观察组HBeAg转阴率较对照组高,差异有统计学意义(P<0.05)。两组总有效率对比,差异无统计学意义(P>0.05)。结论:在慢性乙型肝炎患者治疗中,替诺福韦与恩替卡韦均可达到较好效果,但替诺福韦在改善HBV-DNA水平,提升肝功能方面效果更为明显,有助于HbeAg转阴。

Objective:To explore the clinical effect of Tenofovir and Entecavir in patients with chronic hepatitis B.Method:A total of 100 patients with chronic hepatitis B admitted to the First People's Hospital of Zhangjiachuan Hui Autonomous County of Tianshui from January to October 2021 were selected as the study objects,and they were divided into control group(treated with Entecavir)and observation group(treated with Tenofovir Disoproxil Fumarate Tablets)according to random number table method,with 50 cases in each group.Hepatitis B virus(HBV)-DNA(HBV-DNA)level,liver function,negative conversion rate of hepatitis B e antigen(HBeAg)and total effective rate in the two groups were analyzed.Result:Before treatment,there was no significant difference in HBV-DNA level between the two groups(P>0.05).After 12,24 and 32 weeks of treatment,HBV-DNA levels in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Before and after 32 weeks of treatment,there were no significant differences in liver function indexes between the two groups(P>0.05).After 12 and 24 weeks of treatment,the liver function indexes of the observation group were better than those of the control group,the differences were statistically significant(P<0.05).After 32 weeks of treatment,the HBeAg negative conversion rate in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).There was no significant difference in total effective rate between the two groups(P>0.05).Conclusion:In the treatment of patients with chronic hepatitis B,both Tenofovir and Entecavir can achieve good results,but Tenofovir has a more obvious effect in improving HBV-DNA level and improving liver function,which is helpful to turn HbeAg negative.